Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree®) in Adults肝功能不全对成人单剂量 Viloxazine 缓释胶囊(Qelbree®)药代动力学的影响Clinical Drug InvestigationIF2.72026-07-260OA
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled TrialCLINICAL THERAPEUTICSIF3.62021-04-0134PREAI
THE EFFICACY AND SAFETY OF SPN-812 (VILOXAZINE EXTENDED-RELEASE) FOR THE TREATMENT OF ADHD IN CHILDREN AND ADOLESCENTSJOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRYIF9.52020-10-010PREAI
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age ChildrenCLINICAL THERAPEUTICSIF3.62020-08-0158OAAI
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (P302) ASSESSING THE EFFICACY AND SAFETY OF SPN-812 (EXTENDED-RELEASE VILOXAZINE) 200 AND 400MG FOR THE TREATMENT OF ADHD IN ADOLESCENTSJOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRYIF9.52019-10-010PREAI
LONG-TERM EFFICACY AND SAFETY OF EXTENDED-RELEASE MOLINDONE (SPN-810) TO MANAGE IMPULSIVE AGGRESSION IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER缓释莫林酮 (SPN-810) 治疗注意力缺陷/多动障碍儿童冲动攻击的长期疗效和安全性JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRYIF9.52016-10-010PREAI